Oppenheimer raised the firm’s price target on United Therapeutics (UTHR) to $600 from $575 and keeps an Outperform rating on the shares following quarterly results. The firm says “robust” Q3 financials show the resilience of United Therapeutics’ Treprostinil franchise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $344 from $319 at Ladenburg
- United Therapeutics price target raised to $425 from $400 at H.C. Wainwright
- United Therapeutics Reports Strong Q3 2024 Results
- United Therapeutics reports Q3 EPS $6.93, consensus $6.42
- UTHR Earnings this Week: How Will it Perform?